

1 *Supplementary Materials for*

2 **Point-of-Care microchip electrophoresis for integrated anemia and hemoglobin variant testing**

3  
4 Ran An<sup>1</sup>, Yuncheng Man<sup>1</sup>, Shamreen Iram<sup>2</sup>, Erdem Kucukal<sup>1</sup>, Muhammad Noman Hasan<sup>1</sup>, Ambar Solis-  
5 Fuentes<sup>1</sup>, Allison Bode<sup>1</sup>, Ailis Hill<sup>1</sup>, Kevin Cheng<sup>1</sup>, Sanjay P. Ahuja<sup>3</sup>, Jane A. Little<sup>4</sup>, Michael  
6 Hinczewski<sup>2</sup>, Umut A. Gurkan<sup>1,5,\*</sup>

7  
8 <sup>1</sup>Department of Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH,  
9 USA

10 <sup>2</sup>Department of Physics, Case Western Reserve University, Cleveland, OH, USA

11 <sup>3</sup>Division of Hematology and Oncology, Rainbow Babies and Children's Hospital, Case Western Reserve  
12 University, Cleveland, OH 44106, USA

13 <sup>4</sup>Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill,  
14 NC, USA

15 <sup>5</sup>Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA

16

17 **\* Corresponding author:**

18 Umut A. Gurkan, PhD

19 Warren E. Rupp Associate Professor

20 Case Western Reserve University

21 Office: Glennan 616B, 10900 Euclid Ave., Cleveland, OH 44106.

22 Telephone: +1 (216) 368-6447

23 E-mail: [umut@case.edu](mailto:umut@case.edu)

24 **1. Supplementary Tables**

25 **Table S1.** Clinical Laboratory Standard Institute (CLSI) suggested test subjects for Hb level measurement  
 26 using new technologies

	<b>Total</b>	<b>≤9.0 g/dL</b>	<b>9.1-12.0 g/dL</b>	<b>12.1-17.0 g/dL</b>	<b>≥17.1 g/dL</b>
<b>Sample percentage (CLSI recommended)</b>	100%	15%	25%	50%	10%
<b>Number of Samples (CLSI recommended)</b>	≥40	≥6	≥10	≥20	≥4
<b>Number of Samples (Tested)</b>	46	17	19	10	0
<b>Sample percentage (Tested)</b>	100%	37%	41%	22%	0

27


28

29 **Table S2.** Artificial Neural Network Machine Learning Training

<b>Iteration #</b>	<b>Mean Relative Error (MRE)%</b>
<b>1</b>	6.66312
<b>2</b>	6.13888
<b>3</b>	7.35896
<b>4</b>	6.95064
<b>5</b>	7.38383
<b>6</b>	7.15175
<b>7</b>	7.12065
<b>8</b>	6.66197
<b>9</b>	5.70314
<b>10</b>	7.15175
<b>Average Mean Absolute Error (MAE)</b>	6.83±0.17

30

31 **2. Supplementary Video**



32

33 **Video S1. Overview of HbVA integrated Hb level determination, anemia detection and Hb variant**  
34 **identification**

### 35 3. Efficacy of ANN Based Processing Pipeline

36 For image processing and data analyses of video data generated from the HBVA tests, we utilized an  
37 automated machine learning based protocol. Our goal was to look for signatures encoded in the relative  
38 intensity spectrum obtained from the HbVA data (Hemoglobin vs standard calibrator dye), and correlate  
39 that to the corresponding Hb level for the sample. A detailed breakdown of the analyses workflow and  
40 network details can be found in Methods. To test the efficacy of our Hb level predictor ANN, we used  
41 repeated random sub sampling validation. This involves repeatedly randomly splitting the available dataset  
42 into training and testing groups of fixed sizes. Our initial data set consisted of 68 sample videos, out of  
43 which we used a set of 27 samples for training, and the remaining 41 as the testing set holdout. This choice  
44 of training set size (which is smaller than test set) was made after running many initial training runs on  
45 various set sizes, comparing average training results for each set size, and selecting the smallest set size  
46 that delivered performance comparable to the best achievable performance. We wanted our workflow to be  
47 adaptable to a scenario where availability of data is limited, and optimize for minimal data set size. For  
48 each iteration of the split, the ANN was fit to the training data and evaluated on the testing data. Overall  
49 network performance and a measure of the quality of its predictive power was then obtained by averaging  
50 over the evaluation metrics obtained from each independent training iteration. While k fold cross validation  
51 is a more popular choice, for our problem we needed to design a predictor ANN with a non-traditional  
52 training: testing split. So we wanted to fix our split ratio to this value instead of one determined by the  
53 number of iterations à la k fold cross validation. The quality of each training iteration was evaluated using  
54 the resulting mean absolute relative error (MAE) achieved on the testing set. MAE is computed from the  
55 mean of absolute relative difference between HBVA predicted and observed CBC values i.e.

$$MAE = \frac{1}{n} \sum_{i=1}^n |y_{HBVA} - y_{CBC}| / y_{CBC}$$

56 for a test set of size n. The repeated random sub sampling was run for 10  
57 iterations, yielding an average MAE of 6.83% in testing, which matches/beats human/manual performance  
58 estimates. Results from our repeated sub sampling validation are summarized in Supplementary Table.S2.

59 The testing set was later augmented by a further 5 sample videos from a follow up data set, which played  
60 no part in the sub sampling validation. The network corresponding to the run with MAE closest to the mean  
61 MAE was chosen as the final best version network, and tested on the combined testing set of 46 samples.  
62 Test results for CBC vs HbVA Hb level determination for the combined testing set (completely unseen by  
63 the best version ANN) are shown in **Fig. 5A** in the main text. The solid diagonal line indicates the line of  
64 perfect agreement between the two testing methods. We see how HbVA quantified Hb levels as predicted  
65 by the ANN strongly and accurately correlate with the CBC values, with MAE of 6.2%.

66